Factors influencing blood tumor marker concentrations in the absence of neoplasia
Jaume Trapé,
Esther Fernández-Galán,
Josep Maria Auge
et al.
Abstract:BACKGROUND: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of… Show more
“…Similar to preanalytics, it is crucial to know whether non-malignant clinical or physiological conditions may influence the release, metabolization, or elimination of tumor markers. Trape et al [29] provide a valuable and comprehensive overview of those possibly interfering non-malignant conditions that have to be considered when interpreting tumor marker concentrations in the blood. This is a must have reference for each specialist in laboratory medicine supervising tumor marker measurements, particularly to support clinical validation procedures and in case of clinically doubtful test results.…”
Section: Special Issue On "Lung Cancer Tumor Markers"mentioning
Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring of therapy response in lung cancer patients. The clinical utility of serum tumor markers has considerably increased due to developments in serum protein tumor markers analytics and clinical biomarker studies, the exploration of preanalytical and influencing conditions, the interpretation of biomarker combinations and individual biomarker kinetics, as well as the implementation of biostatistical models. In addition, circulating tumor DNA (ctDNA) and other liquid biopsy markers are playing an increasingly prominent role in the molecular tumor characterization and the monitoring of tumor evolution over time. Thus, modern lung cancer biomarkers may considerably contribute to an individualized companion diagnostics and provide a sensitive guidance for patients throughout the course of their disease. In this special edition on Tumor Markers in Lung Cancer, experts summarize recent developments in clinical laboratory diagnostics of lung cancer and give an outlook on future challenges and opportunities.
“…Similar to preanalytics, it is crucial to know whether non-malignant clinical or physiological conditions may influence the release, metabolization, or elimination of tumor markers. Trape et al [29] provide a valuable and comprehensive overview of those possibly interfering non-malignant conditions that have to be considered when interpreting tumor marker concentrations in the blood. This is a must have reference for each specialist in laboratory medicine supervising tumor marker measurements, particularly to support clinical validation procedures and in case of clinically doubtful test results.…”
Section: Special Issue On "Lung Cancer Tumor Markers"mentioning
Blood-based diagnostics for lung cancer support the diagnosis, estimation of prognosis, prediction, and monitoring of therapy response in lung cancer patients. The clinical utility of serum tumor markers has considerably increased due to developments in serum protein tumor markers analytics and clinical biomarker studies, the exploration of preanalytical and influencing conditions, the interpretation of biomarker combinations and individual biomarker kinetics, as well as the implementation of biostatistical models. In addition, circulating tumor DNA (ctDNA) and other liquid biopsy markers are playing an increasingly prominent role in the molecular tumor characterization and the monitoring of tumor evolution over time. Thus, modern lung cancer biomarkers may considerably contribute to an individualized companion diagnostics and provide a sensitive guidance for patients throughout the course of their disease. In this special edition on Tumor Markers in Lung Cancer, experts summarize recent developments in clinical laboratory diagnostics of lung cancer and give an outlook on future challenges and opportunities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.